Neurizon Therapeutics Limited has released a press release.
PAA & ONJCRI to Continue MPL Pre-clinical Investigations
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- PAA Commences Manufacture of GMP-Grade MPL for Human Trials
- PharmAust to Commence Phase IIb Dog Cancer Trial
- ONJCRI Evaluates Monepantel Anti-Cancer Mechanism
- PAA Evaluate MPL Suitability for Ex-Vivo Human COVID-19 Test
- PAA awarded grant for Phase I trial in Motor Neurone Disease
Later from Neurizon Therapeutics
- Leiden University Medical Centre Monepantel COVID-19 Testing
- Epichem Awarded $200K WasteSorted e-Waste Grant
- Update on Phase IIb Clinical Trial recruitment
- Licensing Agreement to Develop Waste to Fuels Technology
- Update on Phase IIb Clinical Trial of Monepantel in Pet Dogs
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics